Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome
Sponsor: Glostrup University Hospital, Copenhagen
Listed as NCT00673751, this NA trial focuses on Short Bowel Syndrome and remains ongoing. Sponsored by Glostrup University Hospital, Copenhagen, it has been updated 7 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status NA
Status: Enrolling By Invitation → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Glostrup University Hospital, Copenhagen
For direct contact, visit the study record on ClinicalTrials.gov .